The global Cancer Therapy market is expected to witness significant growth owing to the increasing prevalence of various cancers such as lung, colorectal, and other cancers, growing geriatric population base, and technological advancements in sequencing leading to the popularity of personalized/precision medicine. This report will provide an in-depth understanding of the Cancer Therapy market which will further benefit the competitors or stakeholders operating in the Cancer Therapy market, according to the latest report published by DelveInsight “Cancer Therapy Market Insight”
As per DelveInsight analysis, the Cancer Therapy market is expected to grow positively owing to the rising prevalence of various cancers, an increase in the geriatric population, among others. Additionally, the increasing interest in developing targeted therapies to leverage advancements in precision medicine is another prominent factor responsible for the remarkable growth of the Cancer Therapy market.
Interested to know how the cancer therapy market will be growing by 2026? Click to get a snapshot of the Cancer Therapy Market Analysis
Cancer Therapy
Cancer therapy encompasses all kinds of cancer treatments such as chemotherapy, cancer radiation therapy, hormone cancer therapy and targeted cancer therapy among others that aim to kill cancer cells to provide a therapeutic effect.
Cancer, as a chronic and debilitating disease, necessitates comprehensive treatment to eradicate malignant cells. Although not all malignancies necessitate therapy, the vast majority of them do. Various therapies, such as chemotherapy, gene therapy, and immunotherapy, are used in cancer treatment due to the benefits they provide in terms of both curative and palliative effects. These therapies, each with their own advantages, are extremely popular options for cancer treatment.
Cancer Therapy Market Insights
Geographically, the global Cancer Therapy market is studied for North America, Europe, Asia-Pacific, and Rest of the World. In terms of the largest market share, North America is expected to amass a significant revenue share in the global Cancer Therapy market during the forecast period. This can be ascribed to the high prevalence of cancers, and a supportive regulatory environment among other factors in the region. Furthermore, high disposable income, sophisticated healthcare infrastructure, and increased awareness regarding new treatments coupled with extensive insurance coverage for these treatments are also expected to aid in the cancer therapy market growth in this region. However, the superiority of North America will be majorly challenged by the European Cancer Therapy market.
Want to gain a better understanding of why North America is dominating the global cancer therapy market? Click to get a snapshot of the Cancer Therapy Market Outlook
Recent Developments in the Cancer Therapy Market Report
- On April 27, 2022, the FDA has granted Breakthrough Therapy Designation to AstraZeneca and Daiichi Sankyo’s Enhertu for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-negative) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
- On March 17, 2022, the FDA has approved the FoundationOne CDx for use as a companion diagnostic to determine which patients with non–small cell lung cancer (NSCLC) whose tumors harbour EGFR exon 19 deletions or exon 21 (L858R) substitutions may derive benefit from EGFR TKIs that have been greenlit by the agency for this indication.
- On February 21, 2022, the European Commission has approved tepotinib (Tepmetko) for use as a single agent in adult patients with advanced Non-small Cell Lung Cancer (NSCLC)
- On October 15, 2021, the FDA approved atezolizumab (Tecentriq) by Genentech, Inc. for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC).
- On August 2021, Bristol Myers Squibbs received the conditional marketing authorization for Abecma (idecabtagene vicleucel) by the European Commission for the treatment of adult patients with relapsed and refractory multiple myeloma. It is a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.
- On June 2021, the FDA granted the product approval to Elekta AB’s Elekta Harmony radiation therapy system to deliver radiotherapy in the treatment of various cancers such as lung, prostate, and breast cancers.
- Thus, owing to such developments in the market, there will be rapid growth observed in the Cancer Therapy market during the forecast period.
Interested in knowing about the recent developments in cancer therapies? Click to get a snapshot of Therapy for Cancer Treatment
Key Players in the Cancer Therapy Market
Some of the leading Cancer Therapy companies with various new cancer therapy include GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd., and others.
COVID-19 Impact on Cancer Therapy Market Analysis
The Cancer Therapy market was negatively impacted by the implementation of measures to curb the spread of the COVID-19 infection. In order to cater to the exigency created by the COVID-19 pandemic, all other medical specialities witnessed a reduction in patient load. For instance, according to Cancer Research UK, in the UK alone, for example, urgent lung cancer referrals fell by up to 75% during the first lockdown. This did not correlate to the decrease in cases, but fewer people sought and obtained the diagnosis they urgently need. Unfortunately, these trends were prominent across countries around the globe. Nevertheless, the market for cancer therapy is on a period of recovery owing to the devising of strategies to transform cancer care thereby presenting a future outlook for the Cancer Therapy market during the forecast period from 2021-2026.
To gain a better understanding of the short/long-term impact of COVID-19 get a snapshot of the report Cancer Therapy Market Report
Scope of the Cancer Therapy Market Report
- Coverage: Global
- Study Period: 2018-2026
- Market Segmentation By Therapy Type – Chemotherapy, Hormonal Therapy, Targeted Therapy, Radiation Therapy, and Others
- Market Segmentation ByTypes of Cancer – Breast Cancer, Lung Cancer, Prostate Cancer, Blood Cancers, and Others
- Market Segmentation By End-User – Hospitals, Specialty Clinics, and Others
- Market Segmentation By Geography – North America, Europe, Asia-Pacific, and Rest of World
- Key Cancer Therapy Companies – GlaxoSmithKline (LON:GSK), Eli Lilly & Company (NYSE:LLY), F. Hoffmann-La Roche Ltd (SWX:ROG), AbbVie Inc. (NYSE:ABBV), Amgen Inc. (NASDAQ:AMGN), Sanofi (EPN:SAN), Merck & Co., Inc (NYSE:MRK), Novartis AG (SWX:NOVN), Pfizer Inc (NYSE:PFE), AstraZeneca (LON:AZN), Bristol Myers Squibb (NYSE:BMY), Gilead Sciences, Inc. (NASDAQ:GILD), Janssen Global Services, LLC, Elekta AB (STO: EKTA-B), Varian Medical Systems, Inc., Accuray Incorporated (NASDAQ: ARAY), Pyrexar Medical, Eckert & Ziegler (ETR: EUZ), IBA (NYSE: IBA), Panacea Medical Technologies Pvt. Ltd., among others
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
DelveInsight Analysis: The Cancer Therapy market size is expected to grow at a CAGR of 9.12% during the forecast period from 2021 to 2026 to reach USD 266.31 billion by 2026.
Find out which player dominates the cancer therapy market @ Cancer Therapy Companies
Table of Contents
| 1 | Cancer Therapy Market Report Introduction |
| 2 | Cancer Therapy Market Executive summary |
| 3 | Regulatory and Patent Analysis |
| 4 | Cancer Therapy Market Key Factors Analysis |
| 5 | Porter’s Five Forces Analysis |
| 6 | COVID-19 Impact Analysis on Cancer Therapy Market |
| 7 | Cancer Therapy Market Layout |
| 8 | Cancer Therapy Global Company Share Analysis – Key 3-5 Companies |
| 9 | Cancer Therapy Market Company and Product Profiles |
| 10 | Project Approach |
| 11. | About DelveInsight |
Learn more about the CAR-T Cancer Therapy @ Gene Therapy Cancer Treatment
Related Reports
Oncology Drugs Market Insight, Competitive Landscape, and Market Forecast, 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Oncology Drugs companies such as GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, among others.
Intratumoral Cancer Therapies Market
Intratumoral Cancer Therapies Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Intratumoral Cancer Therapies companies such as Daiichi Sankyo, Amgen, Idera Pharmaceuticals, among others.
Liquid Biopsy in Cancer Diagnostics Market
Liquid Biopsy in Cancer Diagnostics Market Insight, Competitive Landscape, and Market Forecast, 2026 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Liquid Biopsy in Cancer Diagnostics companies such as Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, among others.
Metastatic Breast Cancer Pipeline
Metastatic Breast Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Metastatic Breast Cancer companies such as Roche, RemeGen, SynCore Biotechnology, among others.
Metastatic Castration-Sensitive Prostate Cancer Market
Metastatic Castration-Sensitive Prostate Cancer Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Metastatic Castration-Sensitive Prostate Cancer companies such as Astellas Pharma, Pfizer, Janssen Pharmaceutical, among others.
Small Cell Lung Cancer Pipeline
Small Cell Lung Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Small Cell Lung Cancer companies such as Ascentage Pharma, Merck & Co, AstraZeneca, among others.
Other Trending Oncology Reports
- Follicular lymphoma
- Indolent lymphoma
- Severe Toxicities In Lymphoma
- Marginal Zone Lymphoma
- Vulvar Squamous Cell Carcinoma
- Cholangiocarcinoma
- Metastatic Cutaneous Squamous cell Carcinoma
- Nasopharyngeal Carcinoma
- Ductal Carcinoma in Situ
- Oncolytic Virus Cancer Therapy
- Cancer Cachexia
Related Healthcare Blogs
Related Cases Studies
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187